Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?

Jenny D. Beebe, Jing Yuan Liu, Jian-Ting Zhang

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Signal transducer and activator of transcription 3 (STAT3) controls many biological processes including differentiation, survival, proliferation, and angiogenesis. In normal healthy cells, STAT3 is tightly regulated to maintain a momentary active state. However, aberrant or constitutively activated STAT3 has been observed in many different cancers and constitutively activated STAT3 has been shown to associate with poor prognosis and tumor progression. For this reason, STAT3 has been studied as a possible target in the treatment of many different types of cancers. However, despite decades of research, a FDA-approved STAT3 inhibitor has yet to emerge. In this review, we will analyze past studies targeting STAT3 for drug discovery, understand possible causes of failure in these studies, and provide potential insights for future efforts to overcome these roadblocks.

Original languageEnglish (US)
Pages (from-to)74-91
Number of pages18
JournalPharmacology and Therapeutics
Volume191
DOIs
StatePublished - Nov 1 2018

Fingerprint

STAT3 Transcription Factor
Drug Delivery Systems
Research
Biological Phenomena
Neoplasms
Drug Discovery

Keywords

  • cancer therapeutics
  • clinical trials
  • drug discovery
  • molecular probes
  • small molecule compounds
  • STAT3 inhibitor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we? / Beebe, Jenny D.; Liu, Jing Yuan; Zhang, Jian-Ting.

In: Pharmacology and Therapeutics, Vol. 191, 01.11.2018, p. 74-91.

Research output: Contribution to journalReview article

Beebe, Jenny D. ; Liu, Jing Yuan ; Zhang, Jian-Ting. / Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?. In: Pharmacology and Therapeutics. 2018 ; Vol. 191. pp. 74-91.
@article{2dde5e2032f94265819b04858f7881f9,
title = "Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?",
abstract = "Signal transducer and activator of transcription 3 (STAT3) controls many biological processes including differentiation, survival, proliferation, and angiogenesis. In normal healthy cells, STAT3 is tightly regulated to maintain a momentary active state. However, aberrant or constitutively activated STAT3 has been observed in many different cancers and constitutively activated STAT3 has been shown to associate with poor prognosis and tumor progression. For this reason, STAT3 has been studied as a possible target in the treatment of many different types of cancers. However, despite decades of research, a FDA-approved STAT3 inhibitor has yet to emerge. In this review, we will analyze past studies targeting STAT3 for drug discovery, understand possible causes of failure in these studies, and provide potential insights for future efforts to overcome these roadblocks.",
keywords = "cancer therapeutics, clinical trials, drug discovery, molecular probes, small molecule compounds, STAT3 inhibitor",
author = "Beebe, {Jenny D.} and Liu, {Jing Yuan} and Jian-Ting Zhang",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.pharmthera.2018.06.006",
language = "English (US)",
volume = "191",
pages = "74--91",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?

AU - Beebe, Jenny D.

AU - Liu, Jing Yuan

AU - Zhang, Jian-Ting

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Signal transducer and activator of transcription 3 (STAT3) controls many biological processes including differentiation, survival, proliferation, and angiogenesis. In normal healthy cells, STAT3 is tightly regulated to maintain a momentary active state. However, aberrant or constitutively activated STAT3 has been observed in many different cancers and constitutively activated STAT3 has been shown to associate with poor prognosis and tumor progression. For this reason, STAT3 has been studied as a possible target in the treatment of many different types of cancers. However, despite decades of research, a FDA-approved STAT3 inhibitor has yet to emerge. In this review, we will analyze past studies targeting STAT3 for drug discovery, understand possible causes of failure in these studies, and provide potential insights for future efforts to overcome these roadblocks.

AB - Signal transducer and activator of transcription 3 (STAT3) controls many biological processes including differentiation, survival, proliferation, and angiogenesis. In normal healthy cells, STAT3 is tightly regulated to maintain a momentary active state. However, aberrant or constitutively activated STAT3 has been observed in many different cancers and constitutively activated STAT3 has been shown to associate with poor prognosis and tumor progression. For this reason, STAT3 has been studied as a possible target in the treatment of many different types of cancers. However, despite decades of research, a FDA-approved STAT3 inhibitor has yet to emerge. In this review, we will analyze past studies targeting STAT3 for drug discovery, understand possible causes of failure in these studies, and provide potential insights for future efforts to overcome these roadblocks.

KW - cancer therapeutics

KW - clinical trials

KW - drug discovery

KW - molecular probes

KW - small molecule compounds

KW - STAT3 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85049335283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049335283&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2018.06.006

DO - 10.1016/j.pharmthera.2018.06.006

M3 - Review article

C2 - 29933035

AN - SCOPUS:85049335283

VL - 191

SP - 74

EP - 91

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -